The latest from BioStock
» Alzinova completes treatment in the high-dose portion
» Medivir CEO: "Fostrox is unique in its kind"
» Curasight well positioned in hot radiopharmaceutical sector
» The temperature at Cereno Scientific after significant news
» Biosergen advances study with BSG005 against invasive fungus
Read the newsletter for v.43 here.
See all presentations and panels from BioStock Investing in Life Science - here.
The latest news
Devyser Diagnostics Devyser Compact receives Class III regulatory approval in China. Read moreThe company intends to secure FDA approval for NGS tests for monitoring kidney transplants. Read more.
Cantargia reports new results from clinical studies with nadunolimab in several cancers. Read more.
Smell receives an order for Miris HMA to Indonesia. Read more.
Wasps acquisition Paragonix Technologies receives FDA 510(k) clearance for the KidneyVault portable renal perfusion system. Read more.
ADDvise streamlines the organization through a new business area structure. Read more.
BioPorto begins patient recruitment for the US study with ProNephro AKI. Read moreThe company enters into a global distribution partnership with Beckman Coulter. Read more.
IRLAB reports continued progress in preparations for Phase III with mesdopetam. Read more.
Ribocures siRNA product RBD5044 receives clinical trial approval from the Swedish Medical Products Agency for a phase II study in patients with mixed dyslipidemia. Read more.
Cellevate successfully scale up its Cellevat3d nanofiber microcarrier technology. Read more.
First children vaccinated in new clinical study aimed at expanding the indication for Bavarian Nordics Mpox vaccine. Read more.
An American cancer center begins evaluation of Q-lineas AST. Read more.
Lifecare announces completion of development phase of product development agreement with Sanofi. Read more.
Cinclus Pharma announces agreement regarding pediatric study plan with EMA. Read more.
AroCell announces that a new study on the prognostic value of sTK1 in prostate cancer has been published. Read more.
Active Biotech publishes prospectus. Read more.
Q-line postpones the date for the quarterly report. Read more.
Invent Medic appoints Gunilla Nilsson to the new CEO of the company (correction). Read more.
The Nordic industry associations highlight report to EU with recommendations to strengthen the region in life science. Read more.
Reports
Invitation to report presentation
BioInvent Evaxion Biotech IRLAB Therapeutics
Notice of meeting
This morning's price development
Index: OMXS30 +0,38% Healthcare + 0,71 %
| Winner | Förlorare |
| Thor Medical +31,8% | Quia Pharma -15,1% |
| Miris Holding +25,2% | Zenicor -12,5% |
| Active Biotech +18,7% | Lytix Biopharma -8,6% |
| Medim +11,9% | OncoZenge -7,1% |
| Phase Holographic +11,1% | Xintela -6,5% |